Positive Combo Data at ESMO Offers Positive Readthroughs to Surface Oncology (SURF) Adenosine Pathway Assets - BTIG
Tweet Send to a Friend
BTIG analyst Justin Zelin reiterated a Buy rating and $17.00 price target on Surface Oncology (NASDAQ: SURF) after AstraZeneca (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
